

Bortezomib ups response, survival in multiple myeloma

23 July 2012



Image courtesy of Blausen Medical

For patients with newly diagnosed multiple myeloma, induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone followed by bortezomib maintenance therapy improves complete response, progression-free survival, and overall survival rates, according to a study published online July 16 in the *Journal of Clinical Oncology*.

(HealthDay) -- For patients with newly diagnosed multiple myeloma (MM), induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone (PAD) followed by bortezomib maintenance therapy improves complete response (CR), progression-free survival (PFS), and overall survival (OS) rates, according to a study published online July 16 in the *Journal of Clinical Oncology*.

Pieter Sonneveld, M.D., Ph.D., of the Erasmus Medical Center in Rotterdam, Netherlands, and colleagues conducted an open-label, randomized phase III trial involving 827 patients with newly diagnosed, symptomatic MM. Participants were randomized to receive induction therapy with vincristine, [doxorubicin](#), and dexamethasone (VAD) or PAD, followed by high-dose [melphalan](#) and autologous stem-cell transplantation. VAD-treated patients received thalidomide as the maintenance treatment and PAD-treated patients received maintenance [bortezomib](#).

Compared to VAD, the researchers found that PAD induction yielded statistically significant superior CR and near CR rates (31 versus 15 percent). The CR rate was also significantly improved with bortezomib [maintenance therapy](#) (49 versus 34 percent). Compared to those treated with VAD, patients treated with PAD had superior PFS after a median of 41 months (median 35 versus 28 months; hazard ratio, 0.75; P = 0.002) and overall survival was superior in multivariate analysis (hazard ratio, 0.77; P = 0.049). The benefits of bortezomib induction and maintenance therapy were greatest in high-risk patients with creatinine levels in excess of 2 mg/dL and in those with deletion 17p13.

"This randomized multicenter trial in patients with MM who were eligible for high-dose therapy demonstrates that bortezomib during induction and maintenance treatment results in a better response, quality of response, PFS, and OS," the authors write.

The study was funded in part by Janssen-Cilag-Ortho Biotech. Several authors and the German Multicenter Myeloma Group disclosed financial ties to the pharmaceutical industry.

More information: [Abstract](#)
[Full Text](#)
[Editorial](#)

Copyright © 2012 [HealthDay](#). All rights reserved.

APA citation: Bortezomib ups response, survival in multiple myeloma (2012, July 23) retrieved 12 October 2022 from <https://medicalxpress.com/news/2012-07-bortezomib-ups-response-survival-multiple.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.